Futura Medical PLC
FUM
Company Profile
Business description
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction (commercially available in multiple markets), Eroxon Intense (a new line extension in development) and WSD4000 which is in-development female sexual health portfolio. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union followed by USA and rest of the world.
Contact
40 Occam Road
Surrey Technology Centre
GuildfordSurreyGU2 7YG
GBRT: +44 1483685670
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,752.31 | 58.95 | -0.75% |
| DAX 40 | 25,156.73 | 215.02 | -0.85% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,665.86 | 59.17 | -0.55% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |